Jeff Behrens, MS, MBA
President and CEO, Siamab Thereapeutics, Inc.
Jeff is President and CEO of Siamab, a biotech company focused on developing therapeutic antibodies targeting glycan targets in cancer. Previously, Jeff served as Senior Director, Business Development and Operations at Edimer Pharmaceuticals and also worked at Alnylam and Biogen Idec.
In 2003 Jeff sold his healthcare IT company, The Telluride Group, to mindSHIFT Technologies, a Fidelity-funded rollup. Telluride was an information technology managed services provider (MSP) founded in 1995.
Jeff has an MS from the Harvard/MIT Division of Health Sciences and Technology (HST), an MBA from MIT Sloan, and graduated from Harvard College. He lives in Newton, MA.